435 related articles for article (PubMed ID: 33987103)
1. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Liu G; Kang S; Wang X; Shang F
Front Oncol; 2021; 11():669195. PubMed ID: 33987103
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
Zhang C; Liu Y; Tan J; Tian P; Li W
Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
[TBL] [Abstract][Full Text] [Related]
3. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Wu B; Lu S
Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.
Cheng S; Pei R; Li J; Li B; Tang L; Yin T; Liu S
Ann Transl Med; 2021 Sep; 9(18):1481. PubMed ID: 34734033
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy.
Chen P; Yang Q; Li Y; Jing X; Chen J
Front Oncol; 2022; 12():894656. PubMed ID: 36158650
[TBL] [Abstract][Full Text] [Related]
6. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract][Full Text] [Related]
8. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
Front Public Health; 2021; 9():743558. PubMed ID: 34957008
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study.
Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C
Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
Isla D; Lopez-Brea M; Espinosa M; Arrabal N; Pérez-Parente D; Carcedo D; Bernabé-Caro R
Cost Eff Resour Alloc; 2023 Jan; 21(1):6. PubMed ID: 36647072
[TBL] [Abstract][Full Text] [Related]
17. The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab.
Lin S; Li Y; Gu D; Luo S; Huang X; Dong L; Xu X; Lin P; Weng X
Front Oncol; 2022; 12():857452. PubMed ID: 35530317
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
19. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A
J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
